NovaBay Pharmaceuticals Inc
NBY1.820USD
-0.120-6.19%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
10.59MValor de mercado
4.57P/L TTM
Mais detalhes de NovaBay Pharmaceuticals Inc Empresa
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Informações da empresa
Código da empresaNBY
Nome da EmpresaNovaBay Pharmaceuticals Inc
Data de listagemOct 26, 2007
CEOMr. David E. Lazar
Número de funcionários14
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 26
Endereço2000 Powell St Ste 1150
CidadeEMERYVILLE
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal94608-1804
Telefone15108998800
Sitehttps://novabay.com/
Código da empresaNBY
Data de listagemOct 26, 2007
CEOMr. David E. Lazar
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
580.00
-0.34%
Mr. Mijia (Bob) Wu
Mr. Mijia (Bob) Wu
Director
Director
122.00
--
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
92.00
--
Mr. Yongxiang (Sean) Zheng
Mr. Yongxiang (Sean) Zheng
Director
Director
50.00
--
Ms. Julie Garlikov
Ms. Julie Garlikov
Independent Director
Independent Director
50.00
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
26.00
--
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Mr. David E. Lazar
Mr. David E. Lazar
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
580.00
-0.34%
Mr. Mijia (Bob) Wu
Mr. Mijia (Bob) Wu
Director
Director
122.00
--
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
92.00
--
Mr. Yongxiang (Sean) Zheng
Mr. Yongxiang (Sean) Zheng
Director
Director
50.00
--
Ms. Julie Garlikov
Ms. Julie Garlikov
Independent Director
Independent Director
50.00
--
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
26.00
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por EmpresaUSD
Nome
Receita
Proporção
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States
9.78M
100.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Avenova
8.67M
88.67%
Other products
1.07M
10.98%
Other revenue, net
34.00K
0.35%
NeutroPhase
0.00
0.00%
Distribuição de ações
Atualizado em: ter, 19 de ago
Atualizado em: ter, 19 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Poplar Point Capital Management LLC
17.52%
C2C Wealth Management, LLC
1.68%
Geode Capital Management, L.L.C.
0.58%
Rangeley Capital LLC
0.57%
Two Sigma Investments, LP
0.42%
Outro
79.23%
Investidores
Investidores
Proporção
Poplar Point Capital Management LLC
17.52%
C2C Wealth Management, LLC
1.68%
Geode Capital Management, L.L.C.
0.58%
Rangeley Capital LLC
0.57%
Two Sigma Investments, LP
0.42%
Outro
79.23%
Tipos de investidores
Investidores
Proporção
Hedge Fund
18.60%
Investment Advisor
1.75%
Investment Advisor/Hedge Fund
0.58%
Venture Capital
0.35%
Individual Investor
0.02%
Outro
78.70%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
43
1.43M
24.52%
+210.59K
2025Q1
42
1.34M
22.96%
+376.59K
2024Q4
40
546.91K
11.19%
+390.20K
2024Q3
42
126.44K
2.60%
+79.02K
2024Q2
44
12.01K
0.89%
-33.08K
2024Q1
44
12.73K
1.48%
-22.10K
2023Q4
45
34.29K
18.48%
+25.73K
2023Q3
47
15.18K
15.11%
-444.00
2023Q2
47
9.53K
10.53%
-5.30K
2023Q1
51
13.02K
22.50%
-2.13K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Poplar Point Capital Management LLC
1.02M
17.54%
+19.91K
+1.99%
Jun 03, 2025
C2C Wealth Management, LLC
55.00K
0.95%
+4.10K
+8.05%
Mar 31, 2025
Geode Capital Management, L.L.C.
35.00K
0.6%
+1.97K
+5.95%
Mar 31, 2025
Two Sigma Investments, LP
17.47K
0.3%
-13.94K
-44.37%
Mar 31, 2025
XTX Markets LLC
19.85K
0.34%
+3.71K
+22.98%
Mar 31, 2025
Tower Research Capital LLC
5.46K
0.09%
+6.00
+0.11%
Mar 31, 2025
UBS Financial Services, Inc.
749.00
0.01%
+749.00
--
Mar 31, 2025
Hall (Justin M)
580.00
0.01%
-2.00
-0.34%
Mar 18, 2025
The Vanguard Group, Inc.
392.00
0.01%
--
--
May 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Data
Tipo
Proporção
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Apr 18, 2024
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
Nov 14, 2022
Merger
35→1
